Cellyan Biotechnology Co., Ltd HKPD PHARMA
Company Overview
Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers customs clearance, drugs enlisting, warehouse, and other logistics services. In addition, it provides value-added services such as labeling, extended storage, product inspection, batch processing, and logistics support, as well as sales of health supplements and non-pharmaceutical products. The company serves e-commerce platform logistics partners, merchants, and Chinese e-commerce platforms as well as pharmaceutical distributors. The company was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and changed its name to Cellyan Biotechnology Co., Ltd in December 2025. Cellyan Biotechnology Co., Ltd was incorporated in 2023 and is based in Yau Tong, Hong Kong.
Why Investors Should Care
Revenue has grown at a 27.2% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.13.
Recent Developments
- Mar 2025 Revenue of $20.31M (+21.7% YoY); net profit $-27.06K.
- Trailing 12 Months Year-on-year growth — revenue -31.7%, earnings -102.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 27.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 27.20% |
| 1 Year: | -31.70% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -102.03% |
Stock Price Performance
| 1 Year: | -88.31% |
| 6 Months: | -79.52% |
| 3 Months: | -73.70% |
| 1 Month: | -69.38% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)21.31 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 27.2% over 5 years.
CONS
- Trading 92.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 21 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HKPD Cellyan Biotechnology Co., Ltd PHARMA | 0.13 | -1.86 | $5.48M | 0.00% | 2.08% | -15.59% | 27.20% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Revenue | 12.56M | 16.69M | 20.31M |
| Cost of Revenue | 9.82M | 13.13M | 17.90M |
| Gross Profit | 2.74M | 3.56M | 2.42M |
| Operating Expenses | 1.66M | 1.89M | 2.21M |
| Operating Income | 1.08M | 1.67M | 200.77K |
| EBITDA | 1.76M | 2.53M | 1.21M |
| Interest Expense | 23.24K | 82.77K | 97.67K |
| Pretax Income | 1.02M | 1.53M | 36.11K |
| Tax Provision | 22.57K | 196.25K | 63.17K |
| Net Income | 998.20K | 1.33M | -27.06K |
| Diluted EPS | 0.09 | 0.12 | -0.00 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Total Assets | 3.41M | 8.67M | 9.42M | 12.84M |
| Current Assets | 2.75M | 7.80M | 8.73M | 12.33M |
| Cash & Equivalents | 524.61K | 619.58K | 748.72K | 221.84K |
| Inventory | 190.89K | 933.30K | 559.98K | 360.11K |
| Receivables | 1.65M | 3.70M | 4.66M | 3.78M |
| Total Liabilities | 2.82M | 4.41M | 4.43M | 3.26M |
| Current Liabilities | 2.55M | 3.18M | 2.92M | 3.20M |
| Long Term Debt | 116.86K | 1.12M | 1.50M | - |
| Total Debt | 691.08K | 2.09M | 2.37M | 1.26M |
| Total Equity | 585.24K | 4.25M | 4.99M | 9.58M |
| Shares Outstanding | 11.00M | 11.00M | 11.00M | 23.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Operating Cash Flow | 1.73M | -394.33K | 569.21K |
| Investing Cash Flow | -132.09K | -40.80K | -2.45M |
| Financing Cash Flow | -1.16M | 537.32K | 2.00M |
| Capital Expenditure | -117.70K | -88.02K | -154.99K |
| Free Cash Flow | 1.61M | -482.35K | 414.23K |
| Net Change in Cash | 439.31K | 102.19K | 109.36K |
Ratios (Annual)
Figures in %.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Gross Margin % | 21.8% | 21.3% | 11.9% |
| Operating Margin % | 8.6% | 10.0% | 1.0% |
| Net Margin % | 7.9% | 8.0% | -0.1% |
| ROE % | 170.6% | 31.3% | -0.5% |
| ROCE % | 125.7% | 30.5% | 3.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Stonex Group Inc. | 0.93% | 102.31K | $11.61K |
| 2 | Jane Street Group, LLC | 0.45% | 49.09K | $5.57K |
| 3 | HRT Financial LP | 0.38% | 41.82K | $4.75K |
| 4 | Xtx Topco Ltd | 0.35% | 38.93K | $4.42K |
| 5 | Clear Street Group Inc. | 0.11% | 12.02K | $1.36K |
| 6 | UBS Group AG | 0.01% | 1.08K | $122 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HKPD
Live stock, index, futures, Forex and Bitcoin charts on TradingView - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiaEFVX3lxTFBsYWY0MGx3R0hUUW0yNF8yTDJsU0lmbmZnVWlzaXo0NUhXU1R4ZzByb0pLcVhOT3pqZG5xamgzVWtiX2xKSThhVEI0U05uTG8yRUV2b3N5WkQ0TmlUbDJwcVpyRVhTcWtY?oc=5" target="_blank">Live stock, index, futures,…
Which stocks have an unusual volume on Wednesday? - ChartMill
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNMGR6ejFJa3NwNHFoR0N3NU5XOW1TRzE5dWlITGFVMEVPVWJlNWJsTmxybzQydzZyNGNtNk02Y25LenQ0d3NZZ2dDQk54VXFnamJyQl9qR1Y5d1lUZkpyR2NQNEtBY0hzczFHUEZfcDhNUGJlQWFDZmd4azZVdGtmcDE5U195MlRTdlIzWE…
HKPD - Cellyan Biotechnology Co Ltd Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9TSldabV9KZjZlZ1ZIZkJYRkEybENELVpTZ28yWURqY1lwaGxpcDgxNE9PMDF1U2Y0MURZZXd2Qnk4VWFKOXc?oc=5" target="_blank">HKPD - Cellyan Biotechnology Co Ltd Stock Price and Quote</a>  …
Cellyan Biotechnology Receives Nasdaq Extension to Regain Minimum Bid Price Compliance - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPMzVUWjBEUFVOYkJ2dGJyREpuUFhEanRLMWdUeFd0cjNYelItUHk4b1QySktDeWNpNmVHbE5sMXA2eG5yWFZTbURpVFUtbWc4c2lqQ3dUT1pOX21BeVE5UW9OckNCTlFOWUd5VDNpMV9oaEhHNFpQd3hJRTc3UzFzZDNReG40SUpHUlZIWV…
Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNSGw5ZWdMTTI1aEU5Wld6ZTBLeG9VQTVyaXU5azBvWnotQmp5azk4QjJTS0tDWWt2R3YxQXZqdEU0eWt1a1o0ZmJaQnZpOF9oQ1pqV3RZRW43NkhTLW9CcUNwUmM3OFprQWxYMVFxY1ByQk5iVW1vM1pkZldYeXJWMTRrNFpNWG5wRzBMY0…
HKPD|Hong Kong Pharma Digital Technology Holdings Ltd|Price:0.377|Chg%:-0.021 - TradingKey
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTFBoV2ZNT3VqamhqS3piY1RkWEN3Qk9uVm5tVVZzTEd2emJOQkc5bmFEUUxIc0Zna2JRdFpDcTlGQUp4QUxWQXRkSGRyZm9rQ2NzSlJLcmxSYnV4Zw?oc=5" target="_blank">HKPD|Hong Kong Pharma Digital Technology Hold…
HKPD — Frequently Asked Questions
What is the current share price of Cellyan Biotechnology Co., Ltd (HKPD)?
As of 2026-09-19 21:16 PDT, Cellyan Biotechnology Co., Ltd (HKPD) trades at $0.13 on NasdaqCM. Its 52-week range is $0.13 to $1.74.
What is the market capitalisation of HKPD?
Cellyan Biotechnology Co., Ltd (HKPD) has a market capitalisation of $5.48M on NasdaqCM.
What is the P/E ratio of HKPD?
HKPD trades at a trailing price-to-earnings (P/E) ratio of -1.86. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.28.
What is the return on equity (ROE) of HKPD?
HKPD has a return on equity (ROE) of -15.59%. Its return on capital employed (ROCE) is 2.08%.
Is HKPD a good stock to buy?
This page provides a data-driven analysis of Cellyan Biotechnology Co., Ltd (HKPD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.